Generation of donor-specific immunotolerance in renal-allograft recipients
https://doi.org/10.23873/2074-0506-2009-0-1-46-49
Abstract
The kidney cannot be successfully grafted without immunosuppressive therapy. A unicenter retrospective study has evaluated the efficiency of immunosuppression with daclizumab (Zenapax) versus alemtuzumab (Campath).
Subjects and methods. After renal allotransplantation, 64 patients, including 34 and 30 patients, were treated with daclizumab and alemtuzumab, respectively. The absolute count of peripheral blood lymphocytes was measured. Renal grafts were morphologically assessed as described by Banff.
Results. After administration of alemtuzumab, there was a more pronounced decrease in the absolute count of peripheral blood lymphocytes and the rate of acute rejection crisis was 1.5 times lower than that after use of daclizumab.
Conclusion. During the study, alemtuzumab demonstrated a more marked immunosuppressive activity than did daclizumab and the ability of the former to generate donor-specific immunotolerance in renal-allograft recipients.
About the Authors
V. A. Goryainov
Acad. B.V. Petrovsky Russian Surgery Research Center, Russian Academy of Medical Sciences
Russian Federation
Department of Renal Transplantation
Russian Federation
Department of Renal Transplantation
M. M. Kaabak
Acad. B.V. Petrovsky Russian Surgery Research Center, Russian Academy of Medical Sciences
Russian Federation
Department of Renal Transplantation
Russian Federation
Department of Renal Transplantation
M. M. Morozova
Acad. B.V. Petrovsky Russian Surgery Research Center, Russian Academy of Medical Sciences
Russian Federation
Department of Renal Transplantation
Russian Federation
Department of Renal Transplantation
L. A. Shishlo
Acad. B.V. Petrovsky Russian Surgery Research Center, Russian Academy of Medical Sciences
Russian Federation
Department of Renal Transplantation
Russian Federation
Department of Renal Transplantation
N. N. Babenko
Acad. B.V. Petrovsky Russian Surgery Research Center, Russian Academy of Medical Sciences
Russian Federation
Department of Renal Transplantation
Russian Federation
Department of Renal Transplantation
A. K. Zokoyev
Acad. B.V. Petrovsky Russian Surgery Research Center, Russian Academy of Medical Sciences
Russian Federation
Department of Renal Transplantation
Russian Federation
Department of Renal Transplantation
References
1. Calne R.Y., Friend P., Moffiatt S. et al. Probe tolerance, perioperative Campath-1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998;351:601.
2. Calne R.Y., Moffatt S.D., Friend P.J. et al. Campath 1-H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999;68:1613—6.
3. Kirk A.D., Mannon R.B., Kleiner D.E. et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with Alemtuzumab combined with Deoxyspergualin. Transplantation 2005;80(8):1051—8.
4. Knechtle S.I., Pirsch I.D., Fechner J.Jr. et al. Campath-1H induction plus rapamicyn monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003;3:722.
5. Thomas P.G., Ishihara R., Vaidya S. et al. Campath and renal transplant rejection. Clin Transplantation 2004;18(6):759—61.
6. Watson C.J., Firth J., Bradley J. et al. Campath 1-H (Alemtuzumab) in renal transplantation: 5-year comparative follow up. Am J Transplant 2004;4(suppl 8):404.
Review
For citations:
Goryainov V.A., Kaabak M.M., Morozova M.M., Shishlo L.A., Babenko N.N., Zokoyev A.K. Generation of donor-specific immunotolerance in renal-allograft recipients. Transplantologiya. The Russian Journal of Transplantation. 2009;(1):46-49. (In Russ.) https://doi.org/10.23873/2074-0506-2009-0-1-46-49
Views:
717
